Citations (72)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Po-Ting Yeh, Lu-Chun Wang, Shu-Wen Chang, Wei-Shiung Yang, Chung-May Yang & Chang-Hao Yang. (2019) Effect of Fenofibrate on the Expression of Inflammatory Mediators in a Diabetic Rat Model. Current Eye Research 44:10, pages 1121-1132.
Read now
Read now
Jayamanti Pandit & Yasmin Sultana. (2012) Vascular damage of retina in diabetic retinopathy and its treatment. Expert Review of Ophthalmology 7:1, pages 73-86.
Read now
Read now
Kevin Maki1, Mary Dicklin, Andrea Lawless & Matthew Reeves. (2009) Omega-3 fatty acids for the treatment of elevated triglycerides. Clinical Lipidology 4:4, pages 425-437.
Read now
Read now
Articles from other publishers (69)
Sara J. Cromer, Tanayott Thaweethai & Deborah J. Wexler. (2023) Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial. Diabetologia 66:12, pages 2261-2274.
Crossref
Crossref
Dan Zhang, Yicheng Ma, Jianjun Liu, Da Wang, Zuotao Geng, Daiyan Wen, Hang Chen, Hui Wang, Lanyi Li, Xiaotong Zhu, Xuemin Wang, Minshan Huang, Chenggang Zou, Yuanli Chen & Lanqing Ma. (2023) Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. European Journal of Pharmacology, pages 176159.
Crossref
Crossref
Tania Russo, Francesca Coppola, Carla Leite, Marianna Carbone, Debora Paris, Andrea Motta, Anna Di Cosmo, Amadeu M.V.M. Soares, Ernesto Mollo, Rosa Freitas & Gianluca Polese. (2023) An alien metabolite vs. a synthetic chemical hazard: An ecotoxicological comparison in the Mediterranean blue mussel. Science of The Total Environment 892, pages 164476.
Crossref
Crossref
Yu-Fei Wang & Jin-Yue Hu. (2023) Natural and synthetic compounds for glioma treatment based on ROS-mediated strategy. European Journal of Pharmacology 953, pages 175537.
Crossref
Crossref
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang & Pao-Hsien Chu. (2023) The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology 18:7, pages 858-868.
Crossref
Crossref
Erizal Zaini, Fitri Wahyuni, Hulwa Salsabila, Deni Anggraini, Yori Yuliandra & Henny Lucida. (2023) Eutectic Mixture of Fenofibric Acid and Syringic Acid: Improvement of Dissolution Rate and Its Antihyperlipidemic Activity. ChemistrySelect 8:20.
Crossref
Crossref
Seyed Hossein Saadat, Rakhshaneh Goodarzi & Babak Gharaei. (2023) Oral fenofibrate for hyperbilirubinemia in term neonates: A single-blind randomized controlled trial. Journal of Clinical and Translational Science 7:1.
Crossref
Crossref
Melanie Galano, Shereen Ezzat & Vassilios Papadopoulos. (2022) SCP2 variant is associated with alterations in lipid metabolism, brainstem neurodegeneration, and testicular defects. Human Genomics 16:1.
Crossref
Crossref
Ali Mahmoudi, Tannaz Jamialahmadi, Thomas P. Johnston & Amirhossein Sahebkar. (2022) Impact of fenofibrate on NAFLD/NASH: A genetic perspective. Drug Discovery Today 27:8, pages 2363-2372.
Crossref
Crossref
Rene Rodriguez-Gutierrez, Jose Gerardo González, Deven Parmar, Farheen. Shaikh & Pio Cruz-López. (2022) Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. Journal of Lipid Research 63:7, pages 100233.
Crossref
Crossref
Ali Mahmoudi, Seyed Adel Moallem, Thomas P. Johnston & Amirhossein Sahebkar. (2022) Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models. PPAR Research 2022, pages 1-12.
Crossref
Crossref
Ronan Thibaut, Matthew C. Gage, Inès Pineda‐Torra, Gwladys Chabrier, Nicolas Venteclef & Fawaz Alzaid. (2021) Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease. The FEBS Journal 289:11, pages 3024-3057.
Crossref
Crossref
Manon Fantino, Martine Paquette, Chantal Blais, Nathalie Saint-Pierre, Lucienne Bourque, Alexis Baass & Sophie Bernard. (2022) Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study. Nutrition Research 101, pages 43-52.
Crossref
Crossref
Hidekatsu Yanai, Hisayuki Katsuyama & Mariko Hakoshima. (2022) Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. Biomedicines 10:2, pages 401.
Crossref
Crossref
David Travis Thomas, Nicholas R. DelCimmuto, Kyle D. Flack, David E. Stec & Terry D. HindsJr.Jr.. (2022) Reactive Oxygen Species (ROS) and Antioxidants as Immunomodulators in Exercise: Implications for Heme Oxygenase and Bilirubin. Antioxidants 11:2, pages 179.
Crossref
Crossref
Muhammad Yousaf, Valentina Razmovski-Naumovski, Muhammad Zubair, Dennis Chang & Xian Zhou. (2022) Synergistic Effects of Natural Product Combinations in Protecting the Endothelium Against Cardiovascular Risk Factors. Journal of Evidence-Based Integrative Medicine 27, pages 2515690X2211133.
Crossref
Crossref
Matthew Gesner & William H. Frishman. (2022) Drug Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome. Cardiology in Review Publish Ahead of Print.
Crossref
Crossref
Ali Mahmoudi, Alexandra E. Butler, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. BioMed Research International 2021, pages 1-14.
Crossref
Crossref
Wei Zhu, Hongyang Zhao, Fenfen Xu, Bin Huang, Xiaojing Dai, Jikui Sun, Alphonce M. K. Nyalali, Kailiang Zhang & Shilei Ni. (2021) The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas. BMC Cancer 21:1.
Crossref
Crossref
Oshri Avraham, Rui Feng, Eric Edward Ewan, Justin Rustenhoven, Guoyan Zhao & Valeria Cavalli. (2021) Profiling sensory neuron microenvironment after peripheral and central axon injury reveals key pathways for neural repair. eLife 10.
Crossref
Crossref
Yang Xiao, Mindy Kim & Mitchell A. Lazar. (2021) Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. Molecular Metabolism 50, pages 101119.
Crossref
Crossref
Aleesha Shaik & Robert S. Rosenson. (2021) Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy 35:3, pages 677-690.
Crossref
Crossref
Parcival Maissan, Eva Mooij & Matteo Barberis. (2021) Sirtuins-Mediated System-Level Regulation of Mammalian Tissues at the Interface between Metabolism and Cell Cycle: A Systematic Review. Biology 10:3, pages 194.
Crossref
Crossref
D.D. Miceli, V.P. Vidal, M.F.C. Blatter, O.P. Pignataro & V.A. Castillo. (2021) Fenofibrate treatment for severe hypertriglyceridemia in dogs. Domestic Animal Endocrinology 74, pages 106578.
Crossref
Crossref
Deepak Yadav, Prabhakar R. Joshi, Sunil K. Sharma & Rajeev S. Menon. (2020) Regioselective Synthesis of Arylsulfonyl Benzophenones via Aerobic Oxidative [3+3] Benzannulation Reactions. European Journal of Organic Chemistry 2020:40, pages 6370-6374.
Crossref
Crossref
Subrat Das, Jordan McCreary, Shariq Shamim & Tro Kalayjian. (2020) Reversal of severe hypertriglyceridemia with intermittent fasting and a very-low-carbohydrate ketogenic diet: a case series. Current Opinion in Endocrinology, Diabetes & Obesity 27:5, pages 308-311.
Crossref
Crossref
Oshri Avraham, Pan-Yue Deng, Sara Jones, Rejji Kuruvilla, Clay F. Semenkovich, Vitaly A. Klyachko & Valeria Cavalli. (2020) Satellite glial cells promote regenerative growth in sensory neurons. Nature Communications 11:1.
Crossref
Crossref
Qiang Ren, Liming Deng, Zongtao Zhou, Xuekun Wang, Lijun Hu, Rongrong Xie & Zheng Li. (2020) Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM. Bioorganic Chemistry 101, pages 103963.
Crossref
Crossref
Wen-Pin Huang, Wei-Hsian Yin, Jia-Shiong Chen, Po-Hsun Huang, Jaw-Wen Chen & Shing-Jong Lin. (2019) Fenofibrate Reverses Dysfunction of EPCs Caused by Chronic Heart Failure. Journal of Cardiovascular Translational Research 13:2, pages 158-170.
Crossref
Crossref
Shizhan Ma, Shudong Liu, Qi Wang, Lijuan Chen, Ping Yang & Huihuan Sun. (2019) Fenofibrate‐induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 204-207.
Crossref
Crossref
Nan Xu, Qin Wang, Shan Jiang, Qijing Wang, Weipeng Hu, Suhan Zhou, Liang Zhao, Lanyu Xie, Jianghua Chen, Anton Wellstein & En Yin Lai. (2019) Fenofibrate improves vascular endothelial function and contractility in diabetic mice. Redox Biology 20, pages 87-97.
Crossref
Crossref
Khemchand Surana, Bharatkumar Chaudhary, Monika Diwaker & Satyasheel Sharma. (2018) Benzophenone: a ubiquitous scaffold in medicinal chemistry. MedChemComm 9:11, pages 1803-1817.
Crossref
Crossref
Svetlana Cherlin, Maggie Haitian Wang, Heike Bickeböller & Rita M. Cantor. (2018) Detecting responses to treatment with fenofibrate in pedigrees. BMC Genetics 19:S1.
Crossref
Crossref
Hidenori Arai, Shizuya Yamashita, Koutaro Yokote, Eiichi Araki, Hideki SuganamiShun Ishibashi. (2018) Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Atherosclerosis and Thrombosis 25:6, pages 521-538.
Crossref
Crossref
Srilakshmi Srinivasan, Prathibha Hande, Jyoti Shetty & Sindhu Murali. (2018) Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. Indian Journal of Ophthalmology 66:1, pages 98.
Crossref
Crossref
Katarina Bukara, Laurent Schueller, Jan Rosier, Mark A. Martens, Tinne Daems, Loes Verheyden, Siemon Eelen, Michiel Van Speybroeck, Cristian Libanati, Johan A. Martens, Guy Van Den Mooter, Françoise Frérart, Koen Jolling, Marjan De Gieter, Branko Bugarski & Filip Kiekens. (2016) Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man. European Journal of Pharmaceutics and Biopharmaceutics 108, pages 220-225.
Crossref
Crossref
Karel Škoch, Ivana Císařová & Petr Štěpnička. (2016) Synthesis of a Polar Phosphinoferrocene Amidosulfonate Ligand and Its Application in Pd-Catalyzed Cross-Coupling Reactions of Aromatic Boronic Acids and Acyl Chlorides in an Aqueous Medium. Organometallics 35:19, pages 3378-3387.
Crossref
Crossref
Kyeong Soo Kim, Jeong Hyun Kim, Sung Giu Jin, Dong Wuk Kim, Dong Shik Kim, Jong Oh Kim, Chul Soon Yong, Kwan Hyung Cho, Dong Xun Li, Jong Soo Woo & Han-Gon Choi. (2016) Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer. Archives of Pharmacal Research 39:4, pages 531-538.
Crossref
Crossref
Marta Garcia-Ramírez, Cristina Hernández, Xavier Palomer, Manuel Vázquez-Carrera & Rafael Simó. (2015) Fenofibrate prevents the disruption of the outer blood retinal barrier through downregulation of NF-κB activity. Acta Diabetologica 53:1, pages 109-118.
Crossref
Crossref
Kyung Soo Kim, Sung Giu Jin, Omer Mustapha, Abid Mehmood Yousaf, Dong Wuk Kim, Young Hun Kim, Jong Oh Kim, Chul Soon Yong, Jong Soo Woo & Han-Gon Choi. (2015) Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs. International Journal of Pharmaceutics 490:1-2, pages 273-280.
Crossref
Crossref
Rafael Simó, Olga Simó-Servat & Cristina Hernández. (2015) Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?. Current Diabetes Reports 15:5.
Crossref
Crossref
Patricia Bogdanov, Cristina Hernández, Lidia Corraliza, Andrea R. Carvalho & Rafael Simó. (2014) Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetologica 52:1, pages 113-122.
Crossref
Crossref
Thomas Kelder, Lars Verschuren, Ben van Ommen, Alain J van Gool & Marijana Radonjic. (2014) Network signatures link hepatic effects of anti-diabetic interventions with systemic disease parameters. BMC Systems Biology 8:1.
Crossref
Crossref
B. Vergès. (2014) Une nouvelle indication du fénofibrate ? La rétinopathie diabétique, en Australie. Médecine des Maladies Métaboliques 8:5, pages 521-523.
Crossref
Crossref
Hidetoshi Yamada, Eriko Oshiro, Sayaka Kikuchi, Mayuka Hakozaki, Hideyuki Takahashi & Ken-ichi Kimura. (2014) Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs. Journal of Lipid Research 55:5, pages 895-904.
Crossref
Crossref
Ying-Jung Hsu, Lu-Chun Wang, Wei-Shiung Yang, Chung-May Yang & Chang-Hao Yang. (2014) Effects of Fenofibrate on Adiponectin Expression in Retinas of Streptozotocin-Induced Diabetic Rats. Journal of Diabetes Research 2014, pages 1-14.
Crossref
Crossref
Efi Valanti, Alexandros Tsompanidis & Despina Sanoudou. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
259
300
.
Mingming Gao, Le Bu, Yongjie Ma & Dexi Liu. (2013) Concurrent Activation of Liver X Receptor and Peroxisome Proliferator-Activated Receptor Alpha Exacerbates Hepatic Steatosis in High Fat Diet-Induced Obese Mice. PLoS ONE 8:6, pages e65641.
Crossref
Crossref
Faranak Sharifi, Nima Hojeghani, Saeideh Mazloomzadeh & Zahra Shajari. (2013) The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus. Journal of Diabetes & Metabolic Disorders 12:1.
Crossref
Crossref
Natalie Fournier, Véronique Tuloup-Minguez, Marie-Luce Pourci, Patrice Thérond, Jean-Christophe Jullian, Frank Wien, Michel Leroy, Jean Dallongeville, Jean-Louis Paul & Arnaud Leroy. (2013) Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits. Biochimie 95:6, pages 1278-1287.
Crossref
Crossref
Shao-hua Wang, Lu Wang, Yi Zhou, Yi-jing Guo, Yang Yuan, Feng-fei Li, Yan Huang & Wen-qing Xia. (2012) Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital. Diabetes and Vascular Disease Research 10:2, pages 169-178.
Crossref
Crossref
Robert Krysiak, Anna Gdula-Dymek & Bogusław Okopień. (2013) Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological Reports 65:2, pages 429-434.
Crossref
Crossref
Tien Yin Wong, Rafael Simó & Paul Mitchell. (2012) Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?. American Journal of Ophthalmology 154:1, pages 6-12.
Crossref
Crossref
Jan Willem Cohen Tervaert. 2012. Inflammatory Diseases of Blood Vessels. Inflammatory Diseases of Blood Vessels
473
483
.
Elvin Tyrone Price, Gregory James Welder & Issam Zineh. (2012) Modulatory Effect of Fenofibrate on Endothelial Production of Neutrophil Chemokines IL-8 and ENA-78. Cardiovascular Drugs and Therapy 26:2, pages 95-99.
Crossref
Crossref
Maria L. Mansego, Josep Redon, Sergio Martinez-Hervas, Jose T. Real, Fernando Martinez, Sebastian Blesa, Veronica Gonzalez-Albert, Guillermo T. Saez, Rafael Carmena & Felipe J. Chaves. (2011) Different Impacts of Cardiovascular Risk Factors on Oxidative Stress. International Journal of Molecular Sciences 12:9, pages 6146-6163.
Crossref
Crossref
Guenter Haemmerle, Tarek Moustafa, Gerald Woelkart, Sabrina Büttner, Albrecht Schmidt, Tineke van de Weijer, Matthijs Hesselink, Doris Jaeger, Petra C Kienesberger, Kathrin Zierler, Renate Schreiber, Thomas Eichmann, Dagmar Kolb, Petra Kotzbeck, Martina Schweiger, Manju Kumari, Sandra Eder, Gabriele Schoiswohl, Nuttaporn Wongsiriroj, Nina M Pollak, Franz P W Radner, Karina Preiss-Landl, Thomas Kolbe, Thomas Rülicke, Burkert Pieske, Michael Trauner, Achim Lass, Robert Zimmermann, Gerald Hoefler, Saverio Cinti, Erin E Kershaw, Patrick Schrauwen, Frank Madeo, Bernd Mayer & Rudolf Zechner. (2011) ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nature Medicine 17:9, pages 1076-1085.
Crossref
Crossref
Kevin C Maki, Andrea L Lawless, Kathleen M Kelley, Mary R Dicklin, Valerie N Kaden, Arianne L Schild, Tia M Rains & John W Marshall. (2011) Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia. Journal of Cardiovascular Pharmacology 57:4, pages 489-494.
Crossref
Crossref
P. Valensi & S. Picard. (2011) Lipids, lipid-lowering therapy and diabetes complications. Diabetes & Metabolism 37:1, pages 15-24.
Crossref
Crossref
Weihong Li, Daxin Wang, Guohua Song, Chunxia Zuo, Xianfu Qiao & Shucun Qin. (2010) The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats. Lipids in Health and Disease 9:1.
Crossref
Crossref
Michiel Van Speybroeck, Randy Mellaerts, Raf Mols, Thao Do Thi, Johan Adriaan Martens, Jan Van Humbeeck, Pieter Annaert, Guy Van den Mooter & Patrick Augustijns. (2010) Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. European Journal of Pharmaceutical Sciences 41:5, pages 623-630.
Crossref
Crossref
Jaeyoung Ko, Hoosang Hwang, Jungwook Chin, Dongyup Hahn, Jaehwan Lee, Inho Yang, Kyoungjin Shin, Jungyeob Ham & Heonjoong Kang. (2010) A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities. Bioorganic & Medicinal Chemistry Letters 20:20, pages 6017-6019.
Crossref
Crossref
Melvyn Rubenfire, Robert D. Brook & Robert S. Rosenson. (2010) Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events. The American Journal of Medicine 123:10, pages 892-898.
Crossref
Crossref
P. Costet, M.M. Hoffmann, B. Cariou, B. Guyomarc’h Delasalle, T. Konrad & K. Winkler. (2010) Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 212:1, pages 246-251.
Crossref
Crossref
Pengxiang HuangVikas ChandraFraydoon Rastinejad. (2010) Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics. Annual Review of Physiology 72:1, pages 247-272.
Crossref
Crossref
P. J. Simpson-Haidaris, S. J. Pollock, S. Ramon, N. Guo, C. F. Woeller, S. E. Feldon & R. P. Phipps. (2010)
Anticancer Role of PPAR
Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes
. PPAR Research 2010, pages 1-36.
Crossref
Crossref
Sriram Ramanan, Weiling Zhao, David R. Riddle & Mike E. Robbins. (2010) Role of PPARs in Radiation-Induced Brain Injury. PPAR Research 2010, pages 1-12.
Crossref
Crossref
Rafael SimóCristina Hernández. (2009) Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care 32:8, pages 1556-1562.
Crossref
Crossref
Robert S Rosenson & Bertram Pitt. (2008) Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nature Clinical Practice Cardiovascular Medicine 6:2, pages 98-100.
Crossref
Crossref